Keros Therapeutics adds $5 million share buyback
Alpha Vantage · Yahoo! Finance Canada · · AI-summarised by FinFlash
Keros Therapeutics' board approved a new $5 million share repurchase program for its common stock, allowing management to buy shares in the open market with timing and amount dependent on market conditions. The authorization follows receipt of a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A. tied to the ELRiSE MF clinical trial.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.